Pharmaceutical company Eisai Inc. has named a senior vice president for global medical affairs in its oncology business group, it announced Friday.
Dr. Kirk Shepard will create and oversee global oncology medical strategies for the commercial and market access businesses of the U.S. pharma subsidiary of Tokyo-based Eisai Co. Ltd.
The Woodcliff Lake-based company said Shepard has more than 30 years of experience in oncology. He most recently worked at Shire Pharmaceuticals as senior vice president and head of global medical affairs. He had previously been with Baxalta US Inc., which Shire acquired in June 2016.
“Based on his extensive global experience in medical strategy and supportive tactics for the portfolio of commercialized brands, life cycle management and assistance in the launch of products, Dr. Shepard will be a tremendous asset for Eisai,” Terushige Iike, president of the oncology business group, said in a prepared statement. “We are confident that he will play a key role in the growth of Eisai’s oncology business worldwide.”
Among Shepard’s accomplishments, he currently serves as president of the Medical Affairs Professional Society.”